Subsequently, we tested the expression of STK10 in PRAD by analyzing the RNA-seq data obtained from the TCGA database, and found that STK10 was abundantly expressed in 24 kinds of immune cells infiltrated in PRAD samples, especially in the T cells, the pivotal effector in the anti-tumor response (Figure 1B). The gene discussed is STK10; the disease is prostate adenocarcinoma.